Narcolepsy: treatment and what orexin research shows

What is narcolepsy and how common is it?

Narcolepsy is a chronic neurological disorder of sleep and wakefulness classified among the central disorders of hypersomnolence in the International Classification of Sleep Disorders, third edition (ICSD-3),⁴, with ICD-10 code G47.4. Two forms are recognized: narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy)³. Type 1 results from loss of the hypothalamic neurons that produce orexin, also called hypocretin, a neuropeptide that regulates sleep and wakefulness; this deficiency can be measured in cerebrospinal fluid³.

An epidemiology review placed the prevalence of narcolepsy with cataplexy between 25 and 50 per 100,000 people, with an incidence of 0.74 per 100,000 person-years in the one study available at the time¹. Another clinical series described the disease as affecting 1 in 2,000 people². It is thought to occur in genetically susceptible people, with the HLA-DQB1*0602 allele present in 93% of patients with typical cataplexy versus 17% of controls, probably after an environmental exposure before onset¹².

Symptoms and how narcolepsy is diagnosed

Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone with emotion), disrupted nighttime sleep, sleep paralysis, and hallucinations at sleep onset or on waking³¹⁹. Diagnosis rests on the clinical history and on neurophysiological testing: overnight polysomnography followed by a daytime multiple sleep latency test (MSLT), which looks for a sleep-onset REM period (SOREMP)³.

A low cerebrospinal fluid hypocretin-1 is a highly specific and sensitive biomarker, enough to diagnose type 1³. In the series of 274 patients and 296 controls, values below 110 pg/mL were diagnostic and values above 200 pg/mL were considered normal; the measurement is most useful when cataplexy is present or when the MSLT is hard to interpret, for example in people already taking psychoactive drugs². In the revised ICSD-3 text, a SOREMP on the preceding polysomnography can replace the MSLT when clear-cut cataplexy is present, and the three-month sleepiness requirement was removed for type 1 when cataplexy is clear or orexin deficiency is established, but kept for type 2³. The ICSD-3 changes from the previous classification significantly modified the nosology of narcolepsy⁴.

Standard treatment for narcolepsy today

Treatment of narcolepsy today is symptomatic only³. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline, based on a systematic review and the GRADE method, makes these recommendations for adults with narcolepsy: it strongly recommends modafinil, pitolisant, sodium oxybate and solriamfetol, and conditionally suggests armodafinil, dextroamphetamine and methylphenidate¹⁰¹¹. For children with narcolepsy it conditionally suggests modafinil and sodium oxybate¹⁰. The AASM notes that all interventions were compared with no treatment¹⁰.

Pitolisant, a histamine H3 receptor inverse agonist, illustrates the evidence base. In a randomized, double-blind, placebo-controlled trial of 106 patients with narcolepsy with cataplexy, the weekly cataplexy rate fell 75% with pitolisant and 38% with placebo (rate ratio 0.512), and treatment-related adverse events were more frequent with pitolisant (28% versus 12%), mostly headache, irritability, anxiety and mild-to-moderate nausea¹². An earlier trial compared pitolisant with placebo and with modafinil¹³. These drugs are not peptides, and they improve symptoms without correcting the loss of orexin.

What peptide research has shown: orexin (hypocretin)

Orexins were described in 1998 as a family of hypothalamic neuropeptides and G protein-coupled receptors, initially for their role in feeding behavior⁵. In 1999 two papers linked them to narcolepsy: mice lacking the orexin gene developed a narcolepsy-like phenotype⁶, and canine narcolepsy was caused by a mutation in the hypocretin receptor 2 gene⁷. In humans, a study of six narcolepsy brains showed a global loss of hypocretins, with a single gene mutation in one early-onset case⁸; another study counted an 85% to 95% reduction in hypocretin neurons, with neighboring melanin-concentrating hormone neurons spared⁹. This is mechanistic evidence: it explains why type 1 disease is a disease of a missing peptide.

That suggests replacing the peptide. A 2018 review noted that hypocretin replacement would be the most essential treatment but was still not available clinically; it listed intranasal peptide delivery, small-molecule agonists, neuronal transplantation, gene therapy and immunotherapy, and judged non-peptide receptor agonists the most encouraging¹⁴. In the sources reviewed, no trial was found of orexin A or B given as a treatment to patients with narcolepsy. The human evidence for intranasal orexin A is a double-blind, crossover pilot in 10 healthy men of about 26 years: it raised muscle sympathetic nerve activity (+5.8 versus +2.1 bursts per minute with placebo) without changing blood pressure or heart rate¹⁵. That measures a physiological effect, not improved sleepiness, and it did not include people with narcolepsy. Intranasal orexin has also been explored for age-related cognitive dysfunction, mainly with preclinical data¹⁶.

Orexin receptor agonists: oveporexton and TAK-994

Because orexin is hard to deliver to the brain, industry developed oral small-molecule orexin receptor 2 agonists; these are not peptides but mimic their action³¹⁴. The first in a phase 2 trial was TAK-994, in 73 patients with narcolepsy type 1: it improved sleep latency on the maintenance of wakefulness test by 26.4 to 35.0 minutes versus placebo at 8 weeks, but the trial and its extension were stopped early for hepatic adverse events; 5 patients had clinically important liver-enzyme elevations and 3 met Hy's law criteria for drug-induced liver injury¹⁷.

The successor, oveporexton (TAK-861), showed no hepatotoxicity in phase 2: in 90 participants on oveporexton and 22 on placebo over 8 weeks, sleep latency on the maintenance of wakefulness test changed by 12.5 to 25.4 minutes with the drug versus −1.2 with placebo, and the most common adverse events were insomnia (48%, mostly resolved within a week), urinary urgency (33%) and urinary frequency (32%)¹⁸. Two randomized, placebo-controlled phase 3 trials, First Light (168 participants) and Radiant Light (105), lasting 12 weeks in people aged 16 to 70, showed sleep latency improvements of 14.3 to 19.8 minutes versus −0.4 to −0.8 with placebo, Epworth Sleepiness Scale decreases of −9.7 to −11.8 versus −1.5 to −1.7, and median reductions in weekly cataplexy of 79.0% to 88.8% versus 27.7% to 39.1% with placebo; adverse events occurred in 86% to 89% with oveporexton versus 43% to 54% with placebo¹⁹. Both trials were funded by Takeda¹⁹.

The FDA approved oveporexton (Orzeyful) on August 5, 2026 for narcolepsy type 1²¹. The label indicates it for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients; at the time of the label revision the tablet was listed as a controlled substance with scheduling pending²⁰. It is not a peptide treatment, and it is not approved for narcolepsy type 2 or other hypersomnias.

Safety and contraindications

In the FDA label for oveporexton, in two pooled 12-week phase 3 studies, insomnia occurred in 60%, 55% and 1% of patients on 2 mg twice daily, 1 mg twice daily and placebo; urinary frequency in 58%, 53% and 5%; and urinary urgency in 16%, 15% and 1%²⁰. Creatine phosphokinase elevations above 5 times the upper limit of normal appeared in 11% (21 of 196) of treated patients and 5% (4 of 76) on placebo; two cases had markedly elevated CPK and transaminases and both patients discontinued²⁰. It is contraindicated with strong CYP3A inhibitors²⁰.

For pitolisant, the adverse events reported were headache, irritability, anxiety and nausea, with no serious adverse events over 7 weeks¹². By contrast, orexin receptor antagonists act in the opposite direction: in a 1-year insomnia trial, suvorexant improved subjective total sleep time (38.7 versus 16.0 minutes at month 1) and somnolence was the most common adverse event (13% versus 3% with placebo)²². That finding is consistent with orexin as a wake-promoting system, but that trial was in insomnia, not narcolepsy, and was funded by the manufacturer²². For other peptides studied in sleep, see the guide to sleep and cognition peptides and DSIP: what it is, sleep evidence and safety.

Summary by agent

Frequently asked questions

Can narcolepsy be cured with a peptide? Not according to the sources reviewed: no peptide is approved for narcolepsy, current treatment is symptomatic, and hypocretin replacement is not yet available clinically³¹⁴.

What drug did the FDA just approve for narcolepsy? The FDA approved oveporexton (Orzeyful) on August 5, 2026 for adults with narcolepsy type 1; it is an oral orexin receptor 2 agonist, not a peptide²⁰²¹.

Is orexin related to narcolepsy? Yes. Human narcolepsy brains showed an 85% to 95% loss of hypocretin neurons, and mice lacking orexin and dogs with a receptor 2 mutation develop a similar picture⁶⁷⁹.

How is the diagnosis confirmed? With the clinical history, polysomnography and the MSLT and, when needed, by measuring hypocretin-1 in cerebrospinal fluid, where values below 110 pg/mL were diagnostic²³.

What are the first-choice treatments in adults? The AASM guideline strongly recommends modafinil, pitolisant, sodium oxybate and solriamfetol, and conditionally suggests armodafinil, dextroamphetamine and methylphenidate¹⁰.